UEMS-erikoisala

Psykiatria ja neurokehitys — Sivu 2

Formulation science addressing mental health: catecholaminergic modulation, ADHD, mood disorders, neuropsychological function, and the gut–brain axis as a therapeutic target.

25

dossierit

Täsmämikrobiomi ja suolisto-aivo-akseli

Suolisto-aivo-akseli ADHD:ssa: Mikrobiomivälitteinen dopaminergisten reittien modulaatio

Tieteellisesti validoitujen, mikrobiomiin kohdistuvien ADHD-interventioiden kehittäminen edellyttää kliinisten tulosten heterogeenisuuden hallintaa ja tarkkojen mikrobimekanismien tunnistamista. Stabiilien ja tehokkaiden probioottien tai synbioottien formulointi, joilla on osoitettuja kliinisiä hyötyjä, on edelleen merkittävä haaste.

NeuroinflammationAttention Deficit Disorder with HyperactivityDopamineSerotonin

Räätälöidyt formulaatiot saatavilla

Tarvitsetko molekyylillesi räätälöidyn asiakirjakansion?

Project-specific requirements and next steps are confirmed in writing through the agreed scope.

Request a written scoped quote← Palaa Clinical Matrix -näkymään

RELATED RESOURCES

R&D Hub — All Scientific CategoriesFull library of evidence-based research covering formulation, bioavailability and clinical nutrition.EXPLORE ›Advanced Formulation Technology PlatformProject-specific formulation assessment, evidence review and regulatory pathway are defined in the agreed scope. Manufacturing arrangements and any external testing are confirmed per project.EXPLORE ›Production Formats & MOQ ReferenceHard capsules 150K, softgels 300K, sachets 75K — connect the science to actual industrial thresholds.EXPLORE ›Physician Supplement Brand Contract ManufacturingA project brief defines the formulation, evidence, regulatory path, scope and ownership terms before manufacturing is considered.EXPLORE ›Paid Discovery: R&D Due Diligence EntryTransform research findings into a scoped, confidential manufacturing brief.EXPLORE ›Commercialization Intelligence HubRegulatory and market strategy intelligence for supplement brand decision-makers.EXPLORE ›